BillionToOne Faces Short Report Alleging Kickbacks, Flawed Diagnostic Tests
Short seller Fuzzy Panda accuses BillionToOne of undisclosed Medicaid fraud, illegal kickbacks, and flawed tests in a scathing new report.
Last updated: 2026-11-19 15:19:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Myriad Genetics Inc. (MYGN) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $5.71, with a market capitalization of $531.41M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.74 to $8.09. This page covers its latest market performance, valuation, price trends and company information.
$531.41M | |
$5.54 | |
$5.71 | |
$5.41 | |
$5.53 | |
105.18K | |
2.28M | |
-- | |
$8.09 | |
$2.74 | |
-- | |
2026-09-30 |
Myriad Genetics Inc. (MYGN) is currently trading at $5.71 as of 2026-11-19 15:02:17, up 1.63% ($0.09) from the previous close of $5.53
During today's regular trading session, MYGN has traded between $5.41 and $5.71, with a trading volume of 105.18K shares. The current price is near the upper end of today's range.
Over the past seven days, Myriad Genetics Inc. (MYGN) moved from $5.67 to $5.71, representing a gain of 0.62% ($0.04).
The stock traded between $5.41 and $5.86 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.21 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55.5%
MYGN is currently trading at $5.71, placing it 55.5% of the way from its 52-week low of $2.74 to its 52-week high of $8.09. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 2,700 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Myriad Genetics Inc. and MYGN stock.
Short seller Fuzzy Panda accuses BillionToOne of undisclosed Medicaid fraud, illegal kickbacks, and flawed tests in a scathing new report.
The collaboration is expected to improve the testing experience for patients and health care providers, while creating a foundation for broader Myriad offerings and long-term growth in Japan.Local capabilities designed
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price target from $3 to $6.
Eligible investors can buy real shares of Myriad Genetics Inc. (MYGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MYGN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MYGN shares and USD.
MYGN Shares to USD
1.00 MYGN shares = 5.705 USD
Calculations are estimates based on the latest available price and are for reference only.